New research reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop traditional lifestyle plans.
Research printed in a leading health publication shows that while obese people can lose about a fifth of their total mass while using the jabs, the mass returns at an average rate of nearly a kilo each month once they quit.
"People purchasing such treatments need to be cognizant of the risk of quick weight regain when the therapy concludes," stated researcher Dr. Susan Jebb.
That rate of recovery means a return to original weight within about one and a half years.
Comparing Approaches
The study, which examined 37 of trials involving thousands of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists point out that individuals who shed pounds through diet and exercise generally experience a less rapid weight regain—around 100 grams monthly—post-intervention.
Understanding the Fast Regain
Experts believe the way of the jabs accounts for the amplified rebound.
These medications copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in appetite is uncontrolled, making overeating a significant risk."
A Lifelong Condition?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of weight regain, the treatment should be considered life-long.
This view is supported by pharmaceutical companies, who say that the results "highlight the long-term nature of obesity," akin to managing diseases like diabetes.
Patient Testimonies
People who have stopped the jabs report a powerful return of appetite.
"It was like a switch flipping and you become starving," recalled an individual.
The struggle is exacerbated if individuals have not adopted permanent lifestyle or habit changes during therapy.
Growing Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers caution that while these medications are effective agents for weight loss, they are not a standalone solution and lasting health benefits relies on ongoing lifestyle management.
